Disc Medicine, Inc. (IRON)
| Market Cap | 3.56B +4.9% |
| Revenue (ttm) | n/a |
| Net Income | -243.10M |
| EPS | -6.33 |
| Shares Out | 45.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202,232 |
| Open | 76.52 |
| Previous Close | 76.57 |
| Day's Range | 75.25 - 78.80 |
| 52-Week Range | 40.00 - 99.50 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 127.69 (+63.25%) |
| Earnings Date | Nov 5, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $127.69, which is an increase of 63.25% from the latest price.
News
Disc Medicine price target raised to $104 from $92 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Disc Medicine (IRON) to $104 from $92 and keeps an Overweight rating on the shares.
Disc Medicine Transcript: Jefferies Global Healthcare Conference
Bitopertin’s Phase III readout showed a >70% reduction in phototoxic pain attacks, and NDA resubmission is planned by year-end. Next-year priorities include a European MAA submission and advancing myelofibrosis and PV programs toward Phase III.
Disc Medicine Transcript: UBS Global Biopharma Conference 2026
Bitopertin met all Phase III EPP endpoints, with resubmission expected by year-end 2026 and FDA action targeted for mid-2027. Phase II programs target myelofibrosis anemia, IBD anemia and polycythemia vera, with further data and development plans expected at ASH and in 2027.
Disc Medicine Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
APOLLO’s Phase III success supports a planned porphyria launch, initially targeting ~6,000 engaged patients. Selcodebart and the PV antibody are advancing toward pivotal studies, with launch and trial execution supported by >$1.1 billion in pro forma cash.
Disc Medicine initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Disc Medicine (IRON) with a Buy rating and $132 price target The company has a portfolio of “de-risked disease-modifying treatments” for serious blood disorders by tar...
Disc Medicine price target raised to $127 from $120 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Disc Medicine (IRON) to $127 from $120 and keeps a Buy rating on the shares. The firm cites the APOLLO data for…
Disc Medicine reports Q3 EPS ($1.53), consensus ($1.71)
“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP,” said John Quisel, President…
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Earnings release: Q3 2026
Disc Medicine released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Disc Medicine Quarterly report: Q3 2026
Disc Medicine has published its Q3 2026 quarterly earnings report on November 5, 2026.
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine price target raised to $110 from $100 at Wedbush
Wedbush raised the firm’s price target on Disc Medicine (IRON) to $110 from $100 and keeps an Outperform rating on the shares. The firm notes the company reported positive topline…
Disc Medicine 6M share Secondary priced at $75.00
The deal size was increased to $450M from $350M and priced below last closing price of $79.48. Jefferies, Leerink, Morgan Stanley and Cantor Fitzgerald are acting as joint book running…
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine price target raised to $115 from $83 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Disc Medicine (IRON) to $115 from $83 and keeps a Buy rating on the shares. The firm states that it…
Disc Medicine price target raised to $92 from $90 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $92 from $90 and keeps an Overweight rating on the shares.
Disc Medicine price target raised to $170 from $125 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Disc Medicine (IRON) to $170 from $125 and keeps an Overweight rating on the shares. Disc Medicine reported positive Phase 3 APOLLO…
Disc Medicine price target raised to $124 from $86 at Wells Fargo
Wells Fargo raised the firm’s price target on Disc Medicine (IRON) to $124 from $86 and keeps an Overweight rating on the shares. The firm is raising bitopertin’s approval odds…
Disc Medicine announces $350M common stock, warrants offering
Disc Medicine (IRON) announced the commencement of an underwritten public offering of $350M of shares of its common stock and, in lieu of common stock to certain investors that so…
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Disc Medicine price target raised to $115 from $83 at Truist
Truist raised the firm’s price target on Disc Medicine (IRON) to $115 from $83 and keeps a Buy rating on the shares after the company announced topline results from the…
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management ...
Disc Medicine rises 34.0%
Disc Medicine (IRON) is up 34.0%, or $19.32 to $76.16.
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.